AI in Drug Discovery - A Highly Opinionated Literature Review (Part III)


Following up on Part I and Part II, the third post in this series is a collection of review articles published in 2023 that I found helpful. 

Property Prediction

Machine Learning Methods for Small Data Challenges in Molecular Science
https://pubs.acs.org/doi/full/10.1021/acs.chemrev.3c00189

Practical guidelines for the use of gradient boosting for molecular property prediction
https://jcheminf.biomedcentral.com/articles/10.1186/s13321-023-00743-7

Application of message passing neural networks for molecular property prediction
https://www.sciencedirect.com/science/article/pii/S0959440X23000908?via%3Dihub


Molecular Similarity

Molecular Similarity: Theory, Applications, and Perspectives
https://chemrxiv.org/engage/chemrxiv/article-details/655f59b15bc9fcb5c9354a43


Molecular Representation

From intuition to AI: evolution of small molecule representations in drug discovery
https://academic.oup.com/bib/article/25/1/bbad422/7455245


Docking and Scoring

The Impact of Supervised Learning Methods in Ultralarge High-Throughput Docking
https://pubs.acs.org/doi/10.1021/acs.jcim.2c01471

Deep Learning Strategies for Enhanced Molecular Docking and Virtual Screening
https://chemrxiv.org/engage/chemrxiv/article-details/654a339b48dad2312043870c

A practical guide to machine-learning scoring for structure-based virtual screening
https://www.nature.com/articles/s41596-023-00885-w

Keeping pace with the explosive growth of chemical libraries with structure-based virtual screening
https://wires.onlinelibrary.wiley.com/doi/10.1002/wcms.1678


Explainable AI

A Perspective on Explanations of Molecular Prediction Models
https://pubs.acs.org/doi/10.1021/acs.jctc.2c01235

Explainable AI for Bioinformatics: Methods, Tools and Applications
https://academic.oup.com/bib/article-abstract/24/5/bbad236/7227172?redirectedFrom=fulltext

From Black Boxes to Actionable Insights: A Perspective on Explainable Artificial Intelligence for Scientific Discovery
https://pubs.acs.org/doi/10.1021/acs.jcim.3c01642


Generative Models

Integrating structure-based approaches in generative molecular design
https://www.sciencedirect.com/science/article/pii/S0959440X23000337

Deep generative models for 3D molecular structure
https://www.sciencedirect.com/science/article/pii/S0959440X23000404

Generative Models as an Emerging Paradigm in the Chemical Sciences
https://pubs.acs.org/doi/full/10.1021/jacs.2c13467


Open Source 

Open-Source Machine Learning in Computational Chemistry
https://pubs.acs.org/doi/10.1021/acs.jcim.3c00643


Multiple Instance Learning

Chemical complexity challenge: Is multi-instance machine learning a solution
https://wires.onlinelibrary.wiley.com/doi/10.1002/wcms.1698


Multi-objective Optimization

Computer-aided multi-objective optimization in small molecule discovery
https://www.cell.com/patterns/fulltext/S2666-3899(23)00001-6


Computational Approaches to Targeted Protein Degradation

Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
https://pubs.acs.org/doi/10.1021/acs.jcim.3c00603


Data Related Reviews

Data Sharing in Chemistry: Lessons Learned and a Case for Mandating Structured Reaction Data
https://pubs.acs.org/doi/10.1021/acs.jcim.3c00607







Comments

Post a Comment

Popular posts from this blog

Generative Molecular Design Isn't As Easy As People Make It Look

Image
I was taken aback by a recent CNBC article entitled “ Generative AI will be designing new drugs all on its own in the near future ”.  I should know better than to pay attention to AI articles in the popular press, but I feel that even scientists working in drug discovery may have a skewed perception of what generative AI can and can’t do.  To understand exactly what’s involved, it might be instructive to walk through a typical generative molecular design workflow and point out a few things.  First, these programs are far from autonomous.  Even when presented with a well-defined problem, generative algorithms produce a tremendous amount of nonsense.  Second, domain expertise is essential when sifting through the molecules produced by a generative algorithm.  Without a significant medicinal chemistry background, one can’t make sense of the results.  Third, while a few nuggets exist in the generative modeling output, a lot of work and good old-fashioned c...
Read more

AI in Drug Discovery 2023 - A Highly Opinionated Literature Review (Part I)

Image
Here’s the first part of my review of some interesting machine learning (ML) papers I read in 2023.  As with the previous editions , this shouldn’t be considered a comprehensive review.  The papers covered here reflect my research interests and biases, and I’ve certainly overlooked areas that others consider vital.  This post is pretty long, so I've split it into three parts, with parts II and III to be posted in the next couple of weeks.    I. Docking, protein structure prediction, and benchmarking II. Large Language Models, active learning, federated learning, generative models, and explainable AI III. Review articles 2023 was a bit of a mixed bag for AI in drug discovery.  Several groups reported that the deep learning methods for protein-ligand docking weren’t quite what they were initially cracked up to be.  AlphaFold2 became pervasive, and people started to investigate, with mixed success, the utility of predicted protein structures.  There...
Read more

AI in Drug Discovery - A Highly Opinionated Literature Review (Part II)

Image
Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023.  Some areas, like large language models, are new, and most of the work is at the proof-of-concept stage.  Others, like active learning, are more mature, and several groups are starting to explore nuances of the methods.   Here’s the structure of Part II.  4. Large Language Models 5. Active Learning 6. Federated Learning 7. Generative Models 8. Explainable AI 9. Other Stuff 4. Large Language Models The emergence of GPT-4 and ChatGPT brought considerable attention to large language models (LLMs) in 2023.  In November and December, several large pharmas held “AI Day” presentations featuring LLM applications for clinical trial data analysis. Many of these groups demonstrated the ability of LLMs to ingest large bodies of unstructured clinical data and subsequently generate tables and reports based on natural language queries.  Asid...
Read more